A hole has been blown in Bausch Health's late-stage pipeline, after a follow-up to its top-selling drug product Xifaxan ...

NICE has estimated that around 40% of people with COPD have elevated blood levels of eosinophils and, if half the eligible ...

In the evolving landscape of healthcare professional (HCP) engagement, face-to-face interactions remain a cornerstone. They ...

Collectively, the 100 companies on the list generated revenues of £3.7 billion ($5.06 billion), rising by around £3 billion ...

A new technology elucidated yesterday in the journal Nature has the potential to be a leap forward in DNA synthesis, allowing ...

That is according to the Wall Street Journal, which has said MSD failed to reach an agreement with Revolution on a fair price for the business, which has a cancer-focused pipeline headed by ...

The Bio-Hermes-002 study, involving 1,000 volunteers aged over 60 in the UK, US and Canada, is using finger-prick testing to ...

In this interview conducted during JPM Week in San Francisco, pharmaphorum editor-in-chief Jonah Comstock spoke with Adrian Woolfson, co-founder and CEO of Genyro, and Kaihang Wang, chief scientific ...

Shares in ImmunityBio rose sharply after the company said it has agreed a path with the FDA that will allow it to refile for ...

Sanofi has said it will press ahead with regulatory filings for atopic dermatitis (AD) candidate amlitelimab after reporting ...

Hopstem has already completed phase 1 testing of hNPC01 in China, with encouraging results, and says it has now reached ...

In a statement, NICE said the new guidance for Talzenna will make it an option for around 2,400 people in England and reduce ...